Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $275.42 which represents a decrease of $-2.46 or -0.89% from the prior close of $277.88. The stock opened at $276.26 and touched a low of $273.5 ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

Rep. Andy Ogles (R-Tenn.) proposed an amendment to the U.S. Constitution that would allow President Trump to serve a third ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...